NASDAQ:PDSB PDS Biotechnology (PDSB) Stock Price, News & Analysis $1.09 +0.02 (+1.87%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.10 +0.01 (+0.92%) As of 08/1/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PDS Biotechnology Stock (NASDAQ:PDSB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PDS Biotechnology alerts:Sign Up Key Stats Today's Range$1.02▼$1.0950-Day Range$1.07▼$1.7952-Week Range$0.85▼$4.29Volume221,895 shsAverage Volume462,072 shsMarket Capitalization$49.82 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. Read More PDS Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScorePDSB MarketRank™: PDS Biotechnology scored higher than 33% of companies evaluated by MarketBeat, and ranked 781st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingPDS Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePDS Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about PDS Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.20) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PDS Biotechnology is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PDS Biotechnology is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPDS Biotechnology has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about PDS Biotechnology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.34% of the outstanding shares of PDS Biotechnology have been sold short.Short Interest Ratio / Days to CoverPDS Biotechnology has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in PDS Biotechnology has recently decreased by 15.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPDS Biotechnology does not currently pay a dividend.Dividend GrowthPDS Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.34% of the outstanding shares of PDS Biotechnology have been sold short.Short Interest Ratio / Days to CoverPDS Biotechnology has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in PDS Biotechnology has recently decreased by 15.28%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News SentimentN/A Search Interest2 people have searched for PDSB on MarketBeat in the last 30 days. MarketBeat Follows3 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PDS Biotechnology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of PDS Biotechnology is held by insiders.Percentage Held by InstitutionsOnly 26.84% of the stock of PDS Biotechnology is held by institutions.Read more about PDS Biotechnology's insider trading history. Receive PDSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address PDSB Stock News HeadlinesPDS Biotechnology stock rises after trial meets criteria for expansionJuly 10, 2025 | investing.comPDS Biotechnology Shares Climb Following Trial Expansion MilestoneJuly 10, 2025 | msn.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 2 at 2:00 AM | Brownstone Research (Ad)PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 ResultsJuly 10, 2025 | globenewswire.comPDS Biotechnology Corporation (PDSB) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comPDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCCJune 9, 2025 | globenewswire.comPDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society ...June 3, 2025 | morningstar.comMPDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingJune 2, 2025 | globenewswire.comSee More Headlines PDSB Stock Analysis - Frequently Asked Questions How have PDSB shares performed this year? PDS Biotechnology's stock was trading at $1.63 at the beginning of the year. Since then, PDSB shares have decreased by 33.1% and is now trading at $1.09. How were PDS Biotechnology's earnings last quarter? PDS Biotechnology Corporation (NASDAQ:PDSB) issued its earnings results on Wednesday, May, 14th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04. Read the conference call transcript. Who are PDS Biotechnology's major shareholders? Top institutional shareholders of PDS Biotechnology include Tempus Wealth Planning LLC (0.10%). View institutional ownership trends. How do I buy shares of PDS Biotechnology? Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PDS Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that PDS Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Adobe (ADBE), Broadcom (AVGO) and CrowdStrike (CRWD). Company Calendar Last Earnings5/14/2025Today8/02/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PDSB CIK1472091 Webwww.pdsbiotech.com Phone(800) 208-3343Fax908-790-1212Employees20Year FoundedN/APrice Target and Rating Average Price Target for PDS Biotechnology$9.00 High Price Target$13.00 Low Price Target$7.00 Potential Upside/Downside+725.7%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-150.59% Return on Assets-69.15% Debt Debt-to-Equity Ratio0.29 Current Ratio2.33 Quick Ratio2.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book2.14Miscellaneous Outstanding Shares45,710,000Free Float41,505,000Market Cap$49.82 million OptionableOptionable Beta0.95 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:PDSB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.